FedOpsFedOps
Description
Special Notice – Notice of Intent to Sole Source SOLICITATION NUMBER: 75N98026Q00251 TITLE: Preparation of chemical compounds needed for a Janus kinase 2 (JAK2) enzyme project RESPONSE DATE: May 4, 2026, at 4:00 pm EST. PRIMARY POINT OF CONTACT: Jaddua Johnston jaddua.johnston@mail.nih.gov Phone: 240-569-0006 INTRODUCTION: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The compounds described below are needed for evaluation in brain cancer models in assay models at NCATS. They will allow us to determine the compound targets and provide insight into the specificity for brain cancer cells. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS NAICS code 325199 All Other Basic Organic Chemical Manufacturing @ 1250. This acquisition is NOT set aside for small businesses. REGULATORY AUTHORITY This acquisition will be conducted using FAR Part 12 – Acquisition of Commercial Items in conjunction with FAR Part 13 – Simplified Acquisition Procedures, as applicable. The resultant contract will include all appropriate provisions and clauses in effect through the current Federal Acquisition Circular (FAC). STATUTORY AUTHORITY This acquisition is being conducted under the authority of: FAR 6.302-1 – Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements (41 U.S.C. 3304(a)(1)) DESCRIPTION OF REQUIREMENT: PURPOSE AND OBJECTIVES: JAK2 inhibitors are medications that block the activity of the Janus kinase 2 (JAK2) enzyme, which is involved in signaling pathways related to inflammation and immune response. These inhibitors are used to treat various conditions, including some cancers and inflammatory diseases like rheumatoid arthritis and atopic dermatitis. We have discovered a compound that targets brain cancer cells and we require the synthesis of it an analog for evaluation in various brain-cancer cell targeted assays. These two compounds will be evaluated for their potential for treatment in brain cancer. - (1) 4-amino-N,N-dicyclopropyl-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide; and - (2) N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide. Period of Performance: Two months after receipt of approved order. SCOPE OF WORK General Requirements: Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work below: Specific Requirements: Synthesis of specified two (2) compounds at a 95% purity (confirmed by NMR and LCMS)/ Shall provide NCATS with 10g, 95% purity of 4-amino-N,N-dicyclopropyl-6-ethyl-1-methyl-1,6-dihydroimidazo[4,…
Classification
Place of Performance
Contracting Office
Contacts
Attachments (2)